Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of beta-neoendorphin cas 77739-21-0 in China. Welcome to wholesale bulk high quality beta-neoendorphin cas 77739-21-0 for sale here from our factory. Good service and reasonable price are available.
Beta-Neoendorphin, molecular formula C54H77N13O12, CAS 77739-21-0, commonly white powder. From a molecular structure perspective, beta Neoendorphin is an endogenous opioid peptide with a specific amino acid sequence and spatial conformation. This specific molecular structure endows beta Neoendorphin with unique biological activity, enabling it to bind to corresponding receptors and exert pharmacological effects. In living organisms, their physical properties are closely related to their biological activity. For example, its solubility and stability directly affect its absorption and metabolic processes in the body, thereby affecting its pharmacological effects. Meanwhile, the molecular structure and charge properties of beta Neoendorphin also determine its binding mode and affinity with receptors, thereby determining the strength and specificity of its biological activity.
|
Customized Bottle Caps And Corks:
|
|
|
Chemical Formula |
C54H77N13O12 |
|
Exact Mass |
1100 |
|
Molecular Weight |
1100 |
|
m/z |
1100 (100.0%), 1101 (58.4%), 1102 (16.7%), 1101 (4.8%), 1103 (3.1%), 1102 (2.8%), 1102 (2.5%), 1103 (1.4%) |
|
Elemental Analysis |
C, 58.95; H, 7.05; N, 16.55; O, 17.45 |
Due to the fact that Beta-Neoendorphin is a broad and in-depth research field that involves multiple aspects such as neuroscience, pharmacology, drug design, and biosensors. By conducting in-depth research on its physical properties and application value, we can provide new ideas and methods for the treatment of neurological diseases and pain, drug development, and the design of biosensors. Below, we will provide a detailed introduction to several uses and research directions.
1. As an endogenous opioid peptide, it has broad application prospects in the fields of neuroscience and pharmacology. Its specific molecular structure and physical properties enable it to bind to specific receptors, thereby playing a role in regulating neural transmission and pain perception. Therefore, studying the physical properties of beta Neoendorphin, such as molecular structure, stability, solubility, etc., can help us gain a deeper understanding of its pharmacological mechanisms and provide new ideas and methods for the treatment of neurological diseases and pain.
2. It also has important application value in drug design and development. By delving into the relationship between its physical properties and biological activity, we can explore how to optimize the structure of beta Neoendorphin to improve its pharmacological effects and reduce side effects. In addition, the interaction between beta Neoendorphin and other drugs can be studied to develop novel drug combinations with synergistic effects and improve treatment outcomes.
3. It also has potential application value in biosensors and diagnostic technologies. By utilizing its specific physical properties and biometric recognition capabilities, biosensors can be designed and developed for detecting neurotransmitter levels or disease markers. These sensors can achieve early diagnosis and monitoring of related diseases, providing strong support for clinical diagnosis and treatment.
Beta-Neoendorphin, as an endogenous opioid peptide, plays an important regulatory role in the nervous system. Its unique pharmacological properties make it potentially valuable in pain management, neuroprotection, and the treatment of neurodegenerative diseases.
Beta Neoendorphin primarily exerts its pharmacological effects by binding to specific receptors. These receptors are widely distributed in the central and peripheral nervous systems, mediating various physiological and pathological processes. After binding to receptors, beta Neoendorphin can activate a series of signal transduction pathways, thereby regulating the release of neurotransmitters, neuronal excitability, and synaptic plasticity.
Pharmacodynamic characteristics
(1) Analgesic effect: Beta Neoendorphin has a significant analgesic effect and can alleviate various types of pain, including chronic pain, neuropathic pain, etc. Its mechanism of action may be related to regulating pain transmission pathways, inhibiting the release of inflammatory mediators, and affecting the central nervous system's perception and processing of pain.
(2) Neuroprotective effect: Beta Neoendorphin has a protective effect on neurons, which can reduce neuronal damage and death. This protective effect may be related to its antioxidant, anti-inflammatory, and anti apoptotic mechanisms.
(3) Regulating emotions and behaviors: Beta Neoendorphin is also involved in regulating emotions and behaviors, which can affect emotional disorders such as anxiety and depression, as well as cognitive functions such as learning and memory.
3. Pharmacokinetic properties
(1) Absorption and distribution: The absorption and distribution characteristics of beta Neoendorphin in vivo are influenced by various factors, including administration routes, drug dosage forms, and individual differences. Generally speaking, beta Neoendorphin can enter the central nervous system through the blood-brain barrier and exert its effects.
(2) Metabolism and excretion: The metabolic pathways and excretion patterns of beta Neoendorphin in the body are not fully understood, but studies have shown that it may be metabolized by the liver and excreted through the kidneys.
(3) Half life and duration: The half-life and duration of efficacy of beta Neoendorphin depend on factors such as dosage and frequency of administration, as well as individual differences. Generally speaking, its efficacy lasts for a long time and can continue to exert therapeutic effects.
Based on the pharmacological properties of beta Neoendorphin, it has broad application prospects in pain management, neuroprotection, and the treatment of neurodegenerative diseases. At present, some preliminary clinical studies have explored the efficacy and safety of beta Neoendorphin in the treatment of chronic pain, neuropathic pain, and Alzheimer's disease. However, these studies are still in their early stages and require more clinical trials to validate their efficacy and safety.
Activate the Erk1/2 signaling pathway
It can activate the Erk1/2 (extracellular signal regulated kinase 1 and 2) signaling pathway. Erk1/2 is an important member of the MAPK (mitogen activated protein kinase) family, playing a crucial role in cell proliferation, differentiation, apoptosis, and stress response. This substance can affect biological behaviors such as cell growth, survival, and migration by activating the Erk1/2 signaling pathway, thereby affecting the overall physiological functions of the organism. For example, activation of the Erk1/2 signaling pathway can promote cell proliferation and migration, which is of great significance for processes such as tissue repair and wound healing.
Promote matrix metalloproteinase (MMP) activity
It can also promote the activity of matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9. Matrix metalloproteinases are a class of enzymes that can degrade extracellular matrix proteins, playing important roles in extracellular matrix remodeling, tissue repair, inflammatory response, and tumor invasion. It can accelerate the degradation and remodeling of extracellular matrix by promoting the activity of MMP-2 and MMP-9, thereby participating in regulating physiological and pathological processes such as tissue damage repair, inflammatory response, and tumor growth. This mechanism of action is of great significance for maintaining organizational homeostasis and responding to external stimuli.
Analgesic and anti anxiety effects
As an endogenous opioid peptide, Beta Neoendorphin has significant analgesic and anti anxiety effects. These mechanisms of action may be related to their distribution and receptor binding characteristics in the central nervous system. Beta Neoendorphin can trigger a series of biological effects by binding to opioid receptors, with the most significant being its ability to relieve pain. This characteristic makes it play an important role in pain management. At the same time, it may also exert anti anxiety effects by regulating the activity of neurotransmitters and neural networks, thereby improving the emotional state and mental health of patients.
Other potential mechanisms of action
In addition to the main mechanisms of action mentioned above, Beta-Neoendorphin may also have other potential mechanisms of action. For example, it may participate in regulating the function of the immune system, exerting immunomodulatory effects by affecting the proliferation, differentiation, and activity of immune cells. In addition, this substance may also affect various physiological functions of the body through interactions with other neurotransmitters or hormones.
The development prospects of this compound mainly depend on its research progress in the biomedical field, potential clinical applications, market demand, and related technological advancements. The following is a detailed analysis of its development prospects:
Progress in Biomedical Research
As an endogenous peptide substance, it plays an important role in the nervous system and is therefore one of the important research objects in the field of neuroscience. With the continuous deepening of neuroscience research, the understanding of the physiological mechanism of action of this compound will be more comprehensive. This will help reveal the mysteries of the nervous system and the mechanisms of disease occurrence, providing new breakthroughs for the diagnosis and treatment of related diseases.
Potential clinical applications
It has multiple physiological effects, including relieving pain, affecting emotional states, and regulating the endocrine system. These characteristics make the compound potentially valuable for clinical applications in pain management, emotion regulation, and treatment of endocrine disorders. With further research on its pharmacological effects, it is expected to become a new therapeutic drug or adjuvant therapy.
Market demand
With the intensification of global population aging and the continuous increase of chronic pain and other diseases, the demand for effective therapeutic drugs is also continuing to grow. As an endogenous peptide substance with potential therapeutic effects, the market demand for this compound is expected to further expand. Especially in the field of pain management, it may become a new treatment option to meet the needs of more patients.
Technological progress
With the continuous advancement of biotechnology, the extraction, purification, and synthesis techniques of this compound will be continuously optimized. This will help improve its yield and purity, reduce production costs, and thus promote its commercialization process. In addition, the development of new drug delivery systems will also help improve their bioavailability and therapeutic efficacy.
Development prospects and outlook
Taking into account the above factors, its development prospects are relatively broad. With the continuous deepening of biomedical research and the expansion of clinical applications, this compound is expected to become a new therapeutic drug or adjuvant therapy, playing an important role in pain management, emotion regulation, and endocrine disease treatment. Meanwhile, with the continuous advancement of biotechnology and the sustained growth of market demand, its commercialization process will also accelerate further.
In the mid-20th century, scientists began studying chemical signaling molecules in the brain and nervous system.
In 1954, American scientists John Hughes and Hans Kosterlitz first isolated peptides with analgesic effects from pig brains, namely enkephalins (1975). This discovery has sparked extensive research on endogenous opioid peptides.
In the 1970s, researchers discovered various types of endorphins, including alpha endorphins, beta endorphins, and gamma endorphins, all derived from the precursor protein pro melanocortin (POMC) and expressed in the hypothalamus and pituitary gland.
However, scientists have found that the activity of certain endorphins cannot be fully explained by known POMC derived peptides, which has prompted them to search for new endorphin analogs.
In 1981, Japanese scientist Yoshio Tanaka and his team discovered a new opioid active peptide while studying extracts from pig hypothalamus. Its structure is similar to known beta endorphins, but it has stronger receptor binding ability.
They named it Beta Neoendorphin to distinguish it from traditional beta endorphins. In the same year, American scientist Avram Goldstein's team independently isolated similar peptide segments from bovine brain and confirmed their unique opioid receptor activation properties.
These studies collectively established Beta Neoendorphin as a novel endorphin. The amino acid sequence of Beta Neoendorphin was fully elucidated in 1982, and its structure is Tyr Gly Gly Phe Leu Arg Lys Tyr Pro Lys (10 amino acids)
Frequently Asked Questions
Q: Why does β‑neoendorphin show weaker analgesic activity than β‑endorphin in many in vivo assays, despite high μ‑opioid receptor affinity in vitro?
+
-
A: β‑neoendorphin is more rapidly degraded by plasma and brain aminopeptidases, especially by aminopeptidase M and dipeptidyl peptidase. Its shorter half-life in the CNS and poor blood–brain barrier penetration compared to β‑endorphin lead to lower in vivo efficacy despite similar receptor binding.
Q: Does β‑neoendorphin have any non‑opioid biological activities independent of classical opioid receptors?
+
-
A: Yes. At micromolar concentrations, it can weakly modulate immune cell chemotaxis and inhibit macrophage nitric oxide release through non‑opioid membrane binding sites. These effects are not reversed by naloxone and are unrelated to analgesia or reward pathways.
Q: Why is β‑neoendorphin rarely detected in routine neuropeptide profiling of cerebrospinal fluid?
+
-
A: It is stored primarily in posterior pituitary and adrenal medulla rather than in brain parenchyma. It also undergoes rapid N‑terminal truncation and oxidation under standard sampling conditions, leading to low recoveries unless protease inhibitors are added immediately.
Q: Can β‑neoendorphin cause tolerance or physical dependence similar to morphine or other strong opioids?
+
-
A: Under normal physiological concentrations, no. Its rapid metabolic clearance and transient receptor activation prevent sustained downregulation of μ‑opioid receptors. Only at supraphysiological, continuous infusion doses can mild tolerance be observed, which is much weaker than with morphine.
Q: Does the tyrosine residue at position 1 affect the stability of β‑neoendorphin differently from other opioid peptides?
+
-
A: Yes. The N‑terminal Tyr¹ is highly susceptible to monoamine oxidase and radical oxidation, especially under UV light or oxidative stress. Oxidation of this residue abolishes opioid activity completely, whereas many other opioid peptides can retain partial activity after minor oxidation.
Hot Tags: beta-neoendorphin cas 77739-21-0, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 9 9 dimethyl 7 4 4 5 5 tetramethyl 1 3 2 dioxaborolan 2 yl 9H fluorene 2 carbonitril, CAS 2395048 90 3, CAS 56158 60 2, 10 bromobenzo b naphtho 1 2 d furan, 7 10 dichlorobenzo c acridin, 1 bromodibenzo b d furan